Tumour cells have an increased demand for nutrients such as glucose and amino acids. Cancer cells enhance the uptake of glucose and amino acids via increased expression of their transporters. As the imaging modality of glucose uptake within tumour cells, positron emission tomography (PET) with 2-\[^18^F\]-fluoro-2-deoxy-D-glucose (^18^F-FDG) has been widely used for the diagnosis of malignant lesions([@bib30]). ^18^F-FDG PET is based on glucose metabolism, and the overexpression of glucose transporter 1 (Glut1) has been shown to be significantly correlated with ^18^F-FDG uptake in human cancers ([@bib8]). On the other hand, amino-acid transporter systems have an important role in the regulation of cellular proliferation, and an isoform L-type amino-acid transporter 1 (LAT1) is widely expressed in various primary human cancers and cell lines ([@bib18]; [@bib33]; [@bib19]; [@bib23]; [@bib22]; [@bib10]; [@bib26]; [@bib3]; [@bib14], [@bib15]; [@bib1]; [@bib9]). To detect the malignant lesions, we have developed L-\[3-^18^F\]-*α*--methyltyrosine (^18^F-FAMT) as an amino-acid PET tracer for tumour imaging and confirmed its potential usefulness in the detection of various neoplasms ([@bib29]). ^18^F-FAMT is specific to neoplasms, whereas ^18^F-FDG is taken up by non-tumour cells such as inflammation or granulation ([@bib12]). Recent experimental study confirmed that ^18^F-FAMT is selective to LAT1 and is tumour-specific ([@bib32]).^18^F-FAMT PET has been shown to be useful for the cancer diagnosis of non-small cell lung cancer (NSCLC; [@bib13]), oesophageal squamous cell carcinoma (SCC; [@bib28]), oral SCC ([@bib20]; [@bib24]) and multiple myeloma ([@bib7]).The uptake of ^18^F-FAMT has been significantly correlated with the expression of LAT1 in patients with NSCLC; however, little is known about the correlation in other human neoplasms.

Previous studies demonstrated that the expression level of LAT1 is a significant factor for worse prognosis in human cancers such as NSCLC ([@bib10]), urological cancer ([@bib22]), glioma ([@bib23]), prostatic cancer ([@bib26]), gastric cancer ([@bib3]) and pancreatic cancer ([@bib9]). The heavy chain of 4F2 cell surface antigen (CD98) is essential for the functional expression of LAT1 in the plasma membrane ([@bib18]; [@bib14], [@bib9]). LAT1 provides cancer cells with amino acids that are necessary not only for protein synthesis but also for the stimulation of tumour cell growth via mammalian targeting of rapamycin (mTOR; [@bib4]; [@bib14]). Moreover, LAT1 expression yielded a significant correlation with CD98, cell proliferation (Ki-67 labeling index), the cell cycle regulator p53 and angiogenesis in cancer specimens ([@bib14], [@bib9]). As a potential targeting therapy for LAT1, 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH), an inhibitor of system L amino-acid transporter, was investigated using tumour cell lines ([@bib4]). The results of these studies suggest that the inhibition of LAT1 could be effective for various types of cancer.

Oesophageal cancer is a common cancer with a dismal prognosis in patients with advanced stages. To improve the prognosis of patients, clinical markers for predicting therapeutic response as well as effective therapy should be established; however, we have not established biomarker that closely correlates with the prognosis and treatment response ([@bib31]). Previously, we reported that ^18^F-FAMT-PET is useful for the diagnosis of lymph node metastasis in oesophageal cancer ([@bib28]). However, many factors can influence the extent of ^18^F-FAMT accumulation within tumour cells; thus, it remains unclear about the underlying mechanisms for ^18^F-FAMT uptake. Clarifying a relationship between ^18^F-FAMT uptake and the molecular markers including LAT1 may lead to better understanding for the rationale use of ^18^F-FAMT PET in patients.

On the basis of these backgrounds, we conducted a study to confirm the relationship between LAT1 expression and ^18^F-FAMT uptake in patients with oesophageal cancer. In addition, LAT1 expression was compared with CD98, Ki-67 labelling index, cell cycle regulator (p53) and angiogenic markers such as microvessel density (MVD) determined by the CD34 and mTOR signaling pathway. *In vitro* experiments were also performed to investigate the basic mechanism of ^18^F-FAMT uptake.

Materials and methods
=====================

Patients
--------

The current retrospective study included a consecutive series of patients with pathologically confirmed oesophageal squamous cell carcinoma who underwent surgical resection from April 2008 to December 2011. All patients underwent pretreatment work-up with conventional imaging studies. ^18^F-FAMT-PET and ^18^F-FDG-PET were also performed according to the study protocol approved by the institutional review board after providing written informed consent. Patients were excluded from the study if they received previous chemotherapy or radiotherapy before surgical resection and had any concomitant malignancy or heart disease. Therefore, a total of 42 patients were analysed in the study. Tumour stage and disease grade were assigned according to the 6th edition of the tumour, node, metastasis system classification of the International Union Against Cancer. Resectability was determined by the conventional staging methods, which included CT of the neck, chest and abdomen; ^18^F-FDG-PET; endoscopic ultrasonography; and oesophagography.

PET studies and data analysis
-----------------------------

^18^F-FAMT was synthesised in our cyclotron facility according to the method developed by [@bib29]). The radiochemical yield of ^18^F-FAMT was ∼20%, and radiochemical purity was ∼99%. ^18^F-FDG was also produced in our facility as described previously ([@bib25]). The patients fasted for at least 6 h before the PET studies, which were performed using a PET/CT scanner (Discovery STE, GE Healthcare, Pewaukee, WI, USA) with a 700-mm field of view. Three-dimensional data acquisition was initiated 50 min after the injection of 5 MBq kg^−1^ of ^18^F-FAMT or 5 MBq kg^−1^ of ^18^F-FDG ([@bib5]). We acquired 4--10 bed positions (3-min acquisition per bed position) according to the range of the imaging. Attenuation-corrected transverse images obtained with ^18^F-FAMT and ^18^F-FDG were reconstructed with the ordered-subset expectation maximisation algorithm into 128 × 128 matrices with a slice thickness of 3.27 mm. All ^18^F-FDG and ^18^F-FAMT PET images were independently reviewed by two experienced physicians. Uptake that was either moderate or intense was defined as a positive finding on visual interpretation, and either the absence of uptake or uptake that was less than that in normal mediastinum was defined as a negative finding. Discrepant results were resolved by consensus review.

For the semiquantitative analysis, functional images of the standardised uptake value (SUV) were reconstructed using attenuation-corrected transaxial images, the injected dose of ^18^F-FAMT or^18^F-FDG (MBq), the patient\'s body weight (g) and the cross-calibration factor between PET and dose calibrator ([@bib6]). SUV (MBq g^−1^) of the lesion was defined by the region of interest (ROI). A circular ROI of ∼1 cm in diameter was manually drawn on the SUV images over the primary tumour. When the tumour was \>1 cm in diameter or the shape of the tumour was irregular or multifocal, a ROI was drawn over the area corresponding to the maximal tracer uptake. ROI analysis was conducted by a nuclear physician with the aid of corresponding CT scans. The maximal SUV in the ROI (SUV~max~) was used as a representative uptake value for the statistical analyses.

Immunohistochemical staining
----------------------------

LAT1 expression was determined with immunohistochemical staining with an LAT1 antibody (2 mg ml^−1^, anti-human monoclonal mouse antibody, 4A2, provided by Dr H Endou (J-Pharma, Tokyo, Japan), 1 : 3200 dilution). The production and characterisation of the LAT1 antibody has been described previously([@bib26]). CD98 was detected using an affinity-purified rabbit polyclonal antibody (Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA, 1 : 100 dilution) raised against a peptide mapping to the carboxy terminus of human CD98. The detailed protocol for immunostaining has been published elsewhere ([@bib8], [@bib14], [@bib9]). The following antibodies were used: a mouse monoclonal antibody against CD34 (Nichirei, Tokyo, Japan, 1 : 800 dilution); a mouse monoclonal antibody against Ki-67 (Dako, Glostrup, Denmark, 1 : 40 dilution); a mouse monoclonal antibody against p53 (D07; Dako, 1 : 50 dilution); a rabbit polyclonal antibody against GLUT1 (AB15309, Abcam, Tokyo, Japan, 1 : 200 dilution); a mouse monoclonal antibody against EGFR (Novovastra laboratories Ltd., Newcastle, UK, 1 : 100 dilution); a rabbit polyclonal antibody against phospho-Akt (Abcam, 1 : 200 dilution); a rabbit monoclonal antibody against phospho-mTOR (Cell Signaling Technology, Beverly, MA, USA, 1 : 80 dilution). The expression of Glut1 and EGFR was considered positive if distinct membrane staining was present and that of p-Akt and p-mTOR were considered positive if membranous and/or cytoplasmic staining was present. For LAT1, CD98, p-Akt, p-mTOR, Glut1 and EGFR, a semiquantitative scoring method was used as follows: (1) ⩽10% of tumour area stained; (2) 11--25% stained; (3) 26--50% stained; (4) 51--75% stained; and (5) ⩾76% stained. The tumours in which stained tumour cells were scored as 3 or 4 were defined as positive expression. Moreover, the tumours with scoring of 4 or 5 were defined as high expression.

The number of CD34-positive vessels was counted in four selected hotspots in a × 400 field (0.26 mm^2^ field area). MVD was defined as the mean microvessel count per 0.26-mm^2^ field area. The median numbers of CD34-positive vessels were evaluated, and the tumours in which stained tumour cells exceeded the median value were defined as high-expression tumours. For p53, microscopic examination of the nuclear reaction product was performed and scored. A positive p53 expression was defined as expression in more than 10% of the tumour cells. For Ki-67, a highly cellular area of the immunostained sections was evaluated. All epithelial cells with nuclear staining of any intensity were defined as high-expression cells. Approximately 1000 nuclei were counted on each slide. Proliferative activity was assessed as the percentage of Ki-67-stained nuclei (Ki-67 labeling index) in the sample. The median value of the Ki-67 labeling index was evaluated, and the tumours exceeding the median value were defined as high-expression tumours. The sections were assessed using light microscopy in a blinded manner by at least two of the authors.

Cell culture
------------

Human oesophageal cancer cell lines, KYSE30 (JCRB0188) and KYSE150 (JCRB1095), were purchased from the Health Science Research Resources Bank (Osaka, Japan; [@bib27]) and routinely maintained in Dulbecco\'s modified Eagle\'s medium (Wako Pure Chemical Industries, Osaka, Japan) containing 10% heat-inactivated fetal bovine serum (AusGeneX, Loganholme, Queensland, Australia), penicillin (100 units ml^−1^), streptomycin (100 *μ*g ml^−1^) and L-glutamine (2 m[M]{.smallcaps}) at 37 °C in 5% CO~2~ and 95% air.

Immunoblotting
--------------

Cells were dissolved in sample buffer (25% glycerin, 1% SDS, 62.5 m[M]{.smallcaps} Tris-Cl, 10 m[M]{.smallcaps} dithiothreitol) and incubated at 65 °C (LAT1) or 95 °C (CD98 and *β*-actin) for 15 min. Aliquots of samples containing 40 *μ*g of protein were analysed by 10% SDS--polyacrylamide gel electrophoresis and transferred onto a polyvinylidene difluoride membrane. Blots were incubated at 4 °C overnight in 10 m[M]{.smallcaps} Tris--HCl, 100 m[M]{.smallcaps} NaCl, 0.1% Tween 20, pH 7.5 (TBST), with 5% skim milk and then with rabbit anti-LAT1 C-terminus antibody (1 : 5000 dilution; [@bib21]), rabbit anti-LAT1 N-terminus antibody (1 : 5000 dilution; [@bib21]), rabbit anti-CD98 antibody (Santa Cruz Biotechnology, 1 : 200 dilution) or rabbit anti-actin antibody (Cell Signaling Technology, 1 : 1000 dilution) at 4 °C overnight. After having been washed with TBST, the blots were incubated with goat horseradish peroxidase-conjugated anti-rabbit IgG antibody (Cell Signaling Technology,1 : 20 000 dilution) for 1.5 h at room temperature. The blots were further washed with TBST, and specific proteins were visualised by using enhanced chemiluminescence western blotting detection reagents (GE Healthcare).

Cellular uptake studies
-----------------------

Cells (1.0 × 10^5^ cells per well) were plated in the 24-well plates and incubated in the growth medium for 24 h. After the incubation, the cells were washed three times with sodium-free Hunk\'s balanced salt solution (Na^+^-free HBSS; 137 m[M]{.smallcaps} choline chloride, 5.3 m[M]{.smallcaps} KC1, 1.3 m[M]{.smallcaps} CaCl~2~, 0.49 m[M]{.smallcaps} MgCl~2~, 0.41 m[M]{.smallcaps} MgSO~4~, 0.35 m[M]{.smallcaps} K~2~HPO~4~, 0.44 m[M]{.smallcaps} KH~2~PO~4~, 4.2 m[M]{.smallcaps} KHCO~3~, 5.6 m[M]{.smallcaps} D-glucose (pH 7.4)) and then incubated in Na^+^-free HBSS for 10 min. For the ^18^F-FAMT uptake, cells were incubated with 100 kBq (1.5 μ[M]{.smallcaps}) ^18^F-FAMT at 37 °C in Na^+^-free HBSS for 1 min. For inhibition assay of ^18^F-FAMT uptake, cells were incubated in Na^+^-free HBSS containing 100 kBq (1.5 *μ*[M]{.smallcaps}) ^18^F-FAMT and BCH (NARD Institute, Hyogo, Japan) with various concentration (1, 3, 10, 30, 100, 300, 1000, 3000 μ[M]{.smallcaps}) for 1 min. After the incubation, cells were washed three times with ice-cold Na^+^-free HBSS and then lysed with 500 *μ*l of 0.1 [M]{.smallcaps} NaOH. The radioactivity in the cell lysate was measured by a well-type *γ*-counter (ARC-7001, Aloka, Tokyo, Japan).

Expression of LAT mRNA in human oesophageal cancer cells
--------------------------------------------------------

Total RNA was isolated using a NucleoSpin RNA II kit (Macherey-Nagel, Düren, Germany). The first-strand complement DNA was synthesised from 0.5 *μ*g of total RNA with PrimeScript Reverse Transcriptase (Takara Bio, Shiga, Japan). The sequences of specific primers were shown in [Supplementary Table S1](#sup1){ref-type="supplementary-material"} (online only). The real-time PCR analysis was performed by first incubating each complement DNA sample with the primers (0.5 *μ*[M]{.smallcaps} each) and Thunderbird SYBR qPCR Mix (Toyobo, Osaka, Japan). Amplification was carried out for 40 cycles (95 °C for 15 s, 60 °C for 30 s) with Piko-Real thermal cycler (Thermo Fisher Scientific, Waltham, MA, USA). The data were analysed according to 2^−ΔΔ*C*^~t~ method (internal control: *β*-actin, calibrator: LAT1).

Statistical analysis
--------------------

Probability values of \<0.05 indicated a statistically significant difference. Fisher\'s exact test was used to examine the association of two categorical variables. The correlation between different variables was analysed using the nonparametric Spearman\'s rank test. Statistical analysis was performed using the GraphPad Prism 4 software (Graph Pad Software, San Diego, CA, USA) and JMP 8 (SAS, Institute Inc, Cary, NC, USA) for Windows.

Results
=======

PET imaging
-----------

Visual interpretation of the PET images revealed that the primary tumour was visualised by ^18^F-FAMT-PET in 34 patients (80.9%) and ^18^F-FDG-PET in 36 patients (85.7%). The sensitivity for detecting primary tumour was not significantly different between them (*P*=0.771). Representative images of ^18^F-FDG-PET and ^18^F-FAMT-PET are shown in [Figure 1](#fig1){ref-type="fig"}.

The median values of SUV~max~ by^18^F-FAMT and ^18^F-FDG uptake in primary tumours were 2.3 (0.9--5.5) and 7.9 (1.9--40.4), respectively, demonstrating a significant difference (*P*\<0.001). A median value of 2.3 in ^18^F-FAMT-PET was used as the cutoff SUV~max~ in the following analyses and the SUV~max~ more than 2.3 was defined as high uptake, whereas the cutoff value of 7.9 in ^18^F-FDG-PET was used and more than 7.9 was defined as high uptake.

Immunohistochemical analysis
----------------------------

The immunohistochemical analysis was performed on the 42 primary lesions with oesophageal cancer. LAT1 expression was detected in carcinoma cells in the tumour tissues and was localised predominantly on the plasma membrane ([Figure 1C](#fig1){ref-type="fig"}). All positive cells revealed strong membranous LAT1 expression. Cytoplasmic staining was rarely observed. A positive LAT1 and CD98 expression was recognised in 85.7% (36 out of 42) and 80.9% (34 out of 42) of cases, respectively (*P*=0.771). Thirty-three (91.6%) of the 36 patients with positive LAT1 expression overlapped the positive expression of CD98 (33 out of 34, 97.1%). High LAT1 and CD98 expression (score of 4 or 5) was 42.8% (18 out of 42) and 52.3% (22 out of 42) of cases, respectively. All patients (100%) with high LAT1 expression overlapped the expression of CD98. The average LAT1 and CD98 expression scores were 3.5±1.1 and 3.5±1.2 on a scale of 1--5, respectively.

The median number of CD34 was 18 (range 5--36), and the value of 18 was chosen as a cutoff point. The median value for the Ki-67 labelling index was 40% (range, 10--80), and the value of 40% was chosen as a cutoff point. Positive p53 expression was recognised in 71.4% (30 out of 42) of cases. A high expression of Glut1, EGFR, p-Akt and p-mTOR was 85.7% (36 out of 42), 71.4% (30 out of 42), 35.7% (15 out of 42) and 21.4% (9 out of 42), respectively.

Relationship between ^18^F-FAMT uptake and different variables
--------------------------------------------------------------

The result of the statistical correlation according to ^18^F-FAMT uptake is listed in [Table 1](#tbl1){ref-type="table"}. The patients with high ^18^F-FAMT uptake were observed in 47.6% (20 out of 42). High ^18^F-FAMT uptake was significantly associated with lymph node metastasis, disease staging and the expression of LAT1, CD98, Glut1, Ki-67 and CD34.

Correlation between ^18^F-FAMT uptake and different variables
-------------------------------------------------------------

The different biomarkers were correlated with the 34 primary sites that are visualised by both ^18^F-FAMT-PET and ^18^F-FDG PET ([Table 2](#tbl2){ref-type="table"}). ^18^F-FAMT uptake was significantly correlated with LAT1, CD98, Glut1, Ki-67 and CD34 ([Table 2](#tbl2){ref-type="table"}). The uptake of ^18^F-FAMT was closely associated with the expression of LAT1. On the other hand, the 34 primary sites that are visualised by ^18^F-FDG uptake also yielded a significant correlation with LAT1, CD98, Glut1, Ki-67 and CD34 ([Table 3](#tbl3){ref-type="table"}). In all patients (*n*=42), moreover, LAT1 expression was statistically correlated with the expression of CD98, Glut1, Ki-67 and CD34 ([Table 4](#tbl4){ref-type="table"}). [Figures 1D and E](#fig1){ref-type="fig"} showed the correlation between scoring of LAT1 and SUV~max~ by ^18^F-FAMT and between scoring of Glut1 and SUV~max~ by ^18^F-FDG.

^18^F-FAMT was taken up by human oesophageal cancer cell depending on the expression level of LAT1
--------------------------------------------------------------------------------------------------

As shown in [Figure 2A](#fig2){ref-type="fig"}, both LAT1 and CD98 were expressed in oesophageal cancer cell lines; however, the expression level of both proteins in KYSE150 was higher than that in KYSE30, especially for the expression of LAT1. Cellular uptake of ^18^F-FAMT in KYSE150 cells was significantly higher than that in KYSE30 cells consistent with the expression levels of LAT1 and CD98 ([Figure 2B](#fig2){ref-type="fig"}). ^18^F-FAMT uptake was inhibited by the treatment with BCH concentration-dependently in both cell lines ([Figure 2C](#fig2){ref-type="fig"}). Expression profile of LAT1-4 mRNA in KYSE30 and KYSE150 showed that the expression of LAT1 was extremely higher than the other LATs ([Figure 2D](#fig2){ref-type="fig"}). These results indicate that ^18^F-FAMT is taken up through LAT1 and the cellular uptake of ^18^F-FAMT depends on the expression level of LAT1 in oesophageal cancer cells.

Discussion
==========

This is the first study to investigate the underlying mechanism of ^18^F-FAMT uptake in oesophageal cancer. The clinical studies showed that the ^18^F-FAMT uptake was closely correlated with the expression of LAT1, and the high uptake was significantly associated with advanced stage and lymph node metastasis. Pathological analyses revealed significant correlation with CD98, Ki-67 and CD34 as well. LAT1 expression was significantly correlated with CD98, cell proliferation, angiogenesis and glucose metabolism; however, neither LAT1 expression nor ^18^F-FAMT accumulation was significantly associated with the mTOR signaling pathway in patients with oesophageal cancer. *In vitro* study identified that the uptake of ^18^F-FAMT was determined by the expression of LAT1.

Recent studies have described that a LAT1 expression has a crucial role in the tumour progression and metastatic process of various human cancers ([@bib10], [@bib11], [@bib9]). The level of LAT1 expression varies according to histological types of cancer; however, the detailed mechanism remains unclear. In the previous reports, expression of LAT1 was significantly higher in patients with SCC than those with adenocarcinoma (AC). The positive rate in pulmonary SCC was 91% however, those in pulmonary AC, pancreatic cancer, breast cancer, gastric cancer and prostate cancer ranged from 22 from 52.6% ([@bib10], [@bib9]; [@bib26]; [@bib3]; [@bib1]). In the current study, the positive rate was 85.7%, and the LAT1 expression was closely associated with cell proliferation, angiogenesis, glucose metabolism and CD98 expression in oesophageal cancer. Although no statistically significant correlation was observed between LAT1 expression and the mTOR signaling pathway, further study with a large sample size is required to investigate whether the activation of mTOR is essential for the overexpression of LAT1 in oesophageal cancer.

In oesophageal cancer, we also identified that the LAT1 expression was an important mechanism of ^18^F-FAMT uptake within tumour cells. LAT1 is specific to neoplasm, whereas LAT2 is highly expressed in non-neoplastic cells. As ^18^F-FAMT PET visualises LAT1 expression within the tumour, it would be an imaging tool to predict disease stage and metastatic involvement in patients with oesophageal cancer. Recently, we described that the uptake of ^18^F-FAMT was identified as a significant prognostic indicator ([@bib17]) and ^18^F-FAMT PET could be a useful procedure for the monitoring of chemotherapy in lung cancer ([@bib16]). Further study is required to evaluate the clinical significance of ^18^F-FAMT PET as a prognostic marker and treatment monitoring in patients with oesophageal cancer.

Considering ^18^F-FAMT PET as an imaging modality, the lower uptake of ^18^F-FAMT is a limitation. In this study, the uptake of ^18^F-FAMT was significantly lower than that of ^18^F-FDG. Previous studies also demonstrated the same results; however, little is known about the detailed mechanism to explain this finding. The lower uptake leads to poorer delineation of tumours especially in small tumours. In fact the detection rate for tumours was lower for ^18^F-FAMT (81%) compared with ^18^F-FDG (86%), even if the difference did not reach statistical significance. In a recent report, ^18^F-FDG PET demonstrated the sensitivity of 95% (70 of 74 patients) in the primary tumour and has a higher accuracy for the detection of advanced oesophageal disease compared with conventional modalities such as computed tomography ([@bib2]). A higher sensitivity is accompanied by the lower specificity in general and *vice versa*.

In conclusion, the accumulation of ^18^F-FAMT is determined by the presence of LAT1 expression, which has a significant correlation with CD98 expression, cell proliferation and angiogenesis shown by the present *in vitro* studies. A high uptake of ^18^F-FAMT had a close relationship with advanced stage and lymph node metastases. Therefore, inhibiting LAT1 function may provide a new and effective therapeutic target of oesophageal cancer.
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###### 
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![**^18^F-FDG PET/CT (maximum intensity projection image and transaxial section (A) and ^18^F-FAMT PET/CT (maximum intensity projection image and transaxial section; (B) of a 56-year-old man with oesophageal cancer.** ^18^F-FDG PET/CT imaging shows high uptake of ^18^F-FDG by the primary Tumour (SUV~max~, 14.2; *arrows*). ^18^F-FAMT PET/CT imaging shows high uptake of ^18^F-FAMT by the primary tumour (SUV~max~, 4.2; *arrows*). The score of LAT1 immunostaining of the surgically resected primary tumour was 4, and its immunostaining pattern was membranous (**C**).^18^F-FAMT uptake is significantly correlated with LAT1 score (**D**). ^18^F-FDG uptake is significantly correlated with Glut1 score (**E**).](bjc2014142f1){#fig1}

![**LAT1 expression and^18^F-FAMT uptake in human oesophageal cancer. (A) The expression of LAT1 and CD98 in two human oesophageal cancer cell lines, KYSE30 and KYSE150.** *β*-Actin was detected as an internal control. (**B**) ^18^F-FAMT uptake in KYSE150 was significantly higher than that in KYSE30 (*P*\<0.001). (**C**) BCH inhibits ^18^F-FAMT uptake concentration-dependently in both KYSE30 and KYSE150 (*n*=4). Ordinate shows ^18^F-FAMT uptake. (**D**) Expression of LAT1, LAT2, LAT3 and LAT4 mRNA in KYSE30 and KYSE150 (*n*=4). Ordinate shows relative quantity of mRNA calibrated by the amount of LAT1 mRNA.](bjc2014142f2){#fig2}

###### Demographics according to ^18^F-FAMT uptake

  **Variables**                **High** ^**18**^**F-FAMT (*****n*****=20)**   **Low** ^**18**^**F-FAMT (*****n***=**22)**   ***P*****-value**
  ---------------------------- ---------------------------------------------- --------------------------------------------- -------------------
  Age (years, ⩽65/\>65)        11/9                                           10/12                                         0.75
  Sex, M/F                     18/2                                           19/3                                          \>0.999
  Tumour size (mm, ⩽50/\>50)   8/12                                           13/9                                          0.354
  Differentiation, WD-MD/PD    14/6                                           17/5                                          0.729
  Lymph meta, yes/no           16/4                                           10/12                                         **0.028**
  Staging, I+II/III+IV         6/14                                           18/4                                          **0.001**
  Lymphatic invasion, yes/no   18/2                                           15/7                                          0.134
  Vascular invasion, yes/no    17/3                                           13/9                                          0.091
  **LAT1**                                                                                                                  
   High/low                    17/3                                           1/21                                          **\<0.001**
   Positive/negative           20/0                                           16/6                                          **0.022**
  **CD98**                                                                                                                  
   High/low                    18/2                                           4/18                                          **\<0.001**
   Positive/negative           20/0                                           14/8                                          **0.004**
  Glut1, Score 4--5/1--3       18/2                                           11/11                                         **0.007**
  Ki-67, high/low              15/5                                           6/16                                          **\<0.001**
  CD34, high/low               13/7                                           5/17                                          **\<0.001**
  EGFR, high/low               15/5                                           15/7                                          0.738
  p-Akt, high/low              6/14                                           9/13                                          0.531
  p-mTOR, high/low             2/18                                           7/15                                          0.134
  p53, positive/negative       14/6                                           16/6                                          \>0.999

Abbreviations: EGFR=epidermal growth receptor factor; ^18^F-FAMT=L-\[3-^18^F\]-*α*--methyltyrosine; Glut1=glucose transporter 1; LAT1=L-type amino acid transporter 1; M/F=male/female; p-mTOR=phospho-mammalian targeting of rapamycin. The bold entries show statistically significant difference.

###### Correlation according to ^18^F-FAMT uptake (*n*=34)

           **Spearman r**   **95% CI**      ***P*****-value**
  -------- ---------------- --------------- -------------------
  LAT1     0.789            0.609--0.892    **\<0.001**
  CD98     0.765            0.567--0.878    **\<0.001**
  Glut1    0.628            0.359--0.800    **\<0.001**
  Ki-67    0.529            0.222--0.740    **0.001**
  CD34     0.429            0.096--0.676    **0.011**
  EGFR     0.264            −0.092--0.560   0.131
  p-Akt    −0.229           −0.583--0.128   0.191
  p-mTOR   −0.121           −0.449--0.237   0.469

Abbreviations: 95% CI=95% confidence interval; EGFR=epidermal growth receptor factor; ^18^F-FAMT=L-\[3-^18^F\]-*α*--methyltyrosine; Glut1=glucose transporter 1; LAT1=L-type amino-acid transporter 1; p-mTOR=phospho-mammalian targeting of rapamycin. The bold entries show statistically significant difference.

###### Correlation according to ^18^F-FDG uptake (*n*=34)

           **Spearman** ***r***   **95% CI**        ***P*****-value**
  -------- ---------------------- ----------------- -------------------
  LAT1     0.664                  0.411--0.822      **\<0.001**
  CD98     0.734                  0.519--0.862      **\<0.001**
  Glut1    0.616                  0.341--0.794      **\<0.001**
  Ki-67    0.399                  0.061--0.656      **0.019**
  CD34     0.357                  −0.057--0.568     0.036
  EGFR     0.197                  −0.161--0.501     0.263
  p-Akt    −0.093                 −0.427--0.267     0.599
  p-mTOR   −0.159                 −0.181--0.0.199   0.367

Abbreviations: 95% CI=95% confidence interval; EGFR=epidermal growth receptor factor; ^18^F-FAMT=L-\[3-^18^F\]-*α*--methyltyrosine; Glut1=glucose transporter 1; LAT1=L-type amino-acid transporter 1; p-mTOR=phospho-mammalian targeting of rapamycin. The bold entries show statistically significant difference.

###### Correlation according to LAT1 expression (*n*=42)

           **Spearman** ***r***   **95% CI**      ***P*****-value**
  -------- ---------------------- --------------- -------------------
  CD98     0.843                  0.727--0.917    **\<0.001**
  Glut1    0.677                  0.463--0.817    **\<0.001**
  Ki-67    0.427                  0.132--0.652    **0.005**
  CD34     0.632                  0.386--0.783    **\<0.001**
  EGFR     0.248                  −0.068--0.521   0.112
  p-Akt    --0.086                −0.388--0.232   0.587
  p-mTOR   0.057                  −0.463--0.187   0.716

Abbreviations: 95% CI=95% confidence interval; EGFR=epidermal growth receptor factor; ^18^F-FAMT=L-\[3-^18^F\]-*α*--methyltyrosine; Glut1=glucose transporter 1; LAT1=L-type amino-acid transporter 1; p-mTOR=phospho-mammalian targeting of rapamycin. The bold entries show statistically significant difference.

[^1]: These authors equally contributed to this work.
